Literature DB >> 29943722

Iron Deficiency is Prevalent among HIV-Infected Kenyan Adults and is Better Measured by Soluble Transferrin Receptor than Ferritin.

Anne E P Frosch1, George Ayodo2,3, Eliud O Odhiambo3, Kathleen Ireland4,1, John Vulule3, Sarah E Cusick5.   

Abstract

Iron deficiency (ID) and human immunodeficiency virus (HIV) infection frequently coexist. Little data exist on ID in HIV-infected individuals, partly because the iron marker ferritin is altered by inflammation common in HIV infection. We measured iron biomarkers (ferritin, soluble transferrin receptor [sTfR], hepcidin) and red cell indices (hemoglobin, mean corpuscular volume [MCV]) in newly diagnosed, antiretroviral therapy-naive, HIV-infected (N = 138) and uninfected (N = 52) Kenyan adults enrolled in a study of the immune response to malaria. We compared markers between infected and uninfected groups with t test and Wilcoxon Rank-Sum, used Spearman correlation to determine the association between iron and inflammatory markers, and applied logistic regression to determine which markers best predicted anemia. HIV-infected individuals had lower hemoglobin (P < 0.001), lower MCV (P < 0.001), higher sTfR (P = 0.003), and a greater prevalence of ID (sTfR > 8.3 mg/L) than uninfected individuals. Ferritin was elevated in HIV-infected individuals and was more strongly correlated with C-reactive protein (ρ = 0.43, P < 0.001) and hepcidin (ρ = 0.69, P < 0.001) than with hemoglobin. The best predictor of anemia in HIV-infected participants was sTfR, with a one log-unit increase in sTfR associated with a 6-fold increase in the odds of anemia (odds ratio = 6.3, 95% confidence interval: 1.8-21.8). These data suggest a significant burden of ID among treatment-naive HIV-infected Kenyan adults. Soluble transferrin receptor may be a reliable marker of ID in HIV-mediated inflammation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29943722      PMCID: PMC6090357          DOI: 10.4269/ajtmh.18-0208

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  21 in total

1.  Sensitivity, specificity, and predictive value of serum soluble transferrin receptor at different stages of iron deficiency.

Authors:  Jong Weon Choi
Journal:  Ann Clin Lab Sci       Date:  2005       Impact factor: 1.256

2.  Elevated iron status strongly predicts mortality in West African adults with HIV infection.

Authors:  Joann M McDermid; Assan Jaye; Maarten F Schim van der Loeff; Jim Todd; Chris Bates; Steve Austin; David Jeffries; Akum A Awasana; Akum A Whittlex; Andrew Prentice
Journal:  J Acquir Immune Defic Syndr       Date:  2007-12-01       Impact factor: 3.731

3.  Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial.

Authors:  Sunil Sazawal; Robert E Black; Mahdi Ramsan; Hababu M Chwaya; Rebecca J Stoltzfus; Arup Dutta; Usha Dhingra; Ibrahim Kabole; Saikat Deb; Mashavi K Othman; Fatma M Kabole
Journal:  Lancet       Date:  2006-01-14       Impact factor: 79.321

4.  Risk factors and cumulative incidence of anaemia among human immunodeficiency virus-infected children in Uganda.

Authors:  T D Clark; F Mmiro; C Ndugwa; R T Perry; J B Jackson; G Melikian; R D Semba
Journal:  Ann Trop Paediatr       Date:  2002-03

5.  Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS.

Authors:  Simon Swingler; Jin Zhou; Catherine Swingler; Ann Dauphin; Thomas Greenough; Paul Jolicoeur; Mario Stevenson
Journal:  Cell Host Microbe       Date:  2008-07-17       Impact factor: 21.023

Review 6.  Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature.

Authors:  Pamela S Belperio; David C Rhew
Journal:  Am J Med       Date:  2004-04-05       Impact factor: 4.965

7.  Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet       Date:  2016-10-08       Impact factor: 79.321

8.  Iron availability increases the pathogenic potential of Salmonella typhimurium and other enteric pathogens at the intestinal epithelial interface.

Authors:  Guus A M Kortman; Annemarie Boleij; Dorine W Swinkels; Harold Tjalsma
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

9.  Developmental potential in the first 5 years for children in developing countries.

Authors:  Sally Grantham-McGregor; Yin Bun Cheung; Santiago Cueto; Paul Glewwe; Linda Richter; Barbara Strupp
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

10.  Distinct patterns of hepcidin and iron regulation during HIV-1, HBV, and HCV infections.

Authors:  Andrew E Armitage; Andrea R Stacey; Eleni Giannoulatou; Elizabeth Marshall; Pamela Sturges; Kamaljit Chatha; Nicola M G Smith; XiaoJie Huang; XiaoNing Xu; Sant-Rayn Pasricha; Ning Li; Hao Wu; Craig Webster; Andrew M Prentice; Pierre Pellegrino; Ian Williams; Phillip J Norris; Hal Drakesmith; Persephone Borrow
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

View more
  3 in total

1.  Anemia, Iron Status, and HIV: A Systematic Review of the Evidence.

Authors:  Ajibola I Abioye; Christopher T Andersen; Christopher R Sudfeld; Wafaie W Fawzi
Journal:  Adv Nutr       Date:  2020-09-01       Impact factor: 8.701

Review 2.  Nutrition in HIV-Infected Infants and Children: Current Knowledge, Existing Challenges, and New Dietary Management Opportunities.

Authors:  Olufemi K Fabusoro; Luis A Mejia
Journal:  Adv Nutr       Date:  2021-07-30       Impact factor: 8.701

3.  Bone Mineral Density, Body Composition, and Mineral Homeostasis Over 24 Months in Urban South African Women With HIV Exposed to Antiretroviral Therapy.

Authors:  Matthew M Hamill; John M Pettifor; Kate A Ward; Shane A Norris; Ann Prentice
Journal:  JBMR Plus       Date:  2020-03-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.